Numinus Wellness's trial for MDMA-assisted therapy is in pre-implementation stage

Numinus Wellness Inc (CVE:NUMI) (OTCMKTS:LKYSF) (FRA:LR23) updated Thursday on the progress of its first-of-its-kind trial in Canada for MDMA-assisted therapy for treating patients with posttraumatic stress disorder (PTSD). 

The study, which is in collaboration with MAPS Public Benefit Corporation (MAPS PBC), subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), has successfully transitioned into the ‘pre-implementation stage’ at Numinus’ Vancouver clinic, the company said in a statement. 

READ: Numinus Wellness closes acquisition of Mindspace Psychology Services, a leader and pioneer in psychedelic programming

The recruitment of therapists, physicians, and staff is now complete in preparation for enrolling patients and the ultimate analysis of therapy outcomes.

Initial regulatory meetings with Health Canada to define the trial’s implementation science strategy have also been completed, and next steps will include obtaining ethical and Health Canada approvals to allow the recruitment of participants according to coronavirus (COVID-19) public health protocols.

Numinus announced that its Medical and Therapeutic Services Director Dr Devon Christie will serve as both the trial’s Principal Investigator and as a therapist.

Dr. Christie is a family physician with a focus in multidisciplinary pain management, is a certified Relational Somatic Therapist, and is already MAPS-trained in the delivery of the MAPS MDMA-assisted therapy for PTSD.

“I am thrilled to be involved in a long-awaited clinical program that will help pave the way towards wider use of MDMA-assisted psychotherapy for those experiencing PTSD,” said Dr. Christie.

“The key milestones announced today are a true testament to our teams’ commitment to establishing the physical, technical, clinical, and human resource infrastructure needed to swiftly move through the trial’s formal implementation stages and ultimately towards the recruitment of the first participant.”

Numinus Wellness is a health care and research company creating psychedelic-centred solutions to treat mental illness, substance abuse and trauma.

Contact the author at [email protected]

Story by ProactiveInvestors